Adenoid cystic carcinoma (ACC) is unique among salivary gland tumors in both its natural history and in its response to nonsurgical treatment methods (ie, radiation and chemotherapy). The chemotherapeutic agent, cisplatin, seems to be unique in its ability to affect ACC. It might be that ACCs of the minor salivary glands are especially vulnerable to the intra-arterial method of administering this drug, because there are accessible feeding vessels to most locations in which these tumors occur. We have treated four patients with advanced ACC with intra-arterial cisplatin. The responses suggest that this method may be a useful adjunct in the management of this tumor both as a preoperative and as a palliative measure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archotol.1982.00790520021007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Arterial Infusion and Isolated Perfusion in Combination with Reversible Electroporation for Locally Relapsed Unresectable Breast Cancer.
Cancers (Basel)
November 2024
Department Surgical Oncology, Medias Klinikum, 84489 Burghausen, Germany.
Background: Relapsed unresectable triple-negative breast cancer is a demanding disease with only a few treatment options. Especially for patients with unresectable tumor masses, a treatment that offers rapid tumor shrinkage is needed. If patients are exhausted from several treatment lines, systemic side effects have to be avoided.
View Article and Find Full Text PDFCisplatin intra-arterial chemotherapy for recurrent maxillary gingival cancer and metastatic lymph nodes without radiation or surgery: A case report.
Radiol Case Rep
January 2025
Department of Radiology, Sapporo Medical University School of Medicine, South 1 West 17, Chuo-Ku, Sapporo City, Hokkaido 060-8556, Japan.
Most patients with head and neck cancers struggle with their treatment, particularly those with recurrent cancer. However, there is no consensus on effective treatments for recurrent head and neck cancer. Recurrent cases are often challenging to treat because performing both reirradiation and surgical intervention can occasionally be difficult.
View Article and Find Full Text PDFEfficacy analysis of HAIC combined with lenvatinib plus PD1 inhibitor vs. first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma.
Sci Rep
October 2024
Department of Interventonal Medicine, Zhongshan People's Hospital, Guangdong, 528400, China.
This research was intended to compare the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) in conjunction with lenvatinib and PD1 inhibitors to first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma(ICC). The research enrolled advanced ICC patients who underwent HAIC plus lenvatinib and PD1 inhibitor(n = 51) or first-line systemic chemotherapy(cisplatin + gemcitabine, n = 39) between July 2020 to January 2023 in Zhongshan People's Hospital.Their clinical outcomes were assessed through measurement of parameters encompassing objective response rate (ORR), disease control rate (DCR), median overall survival (mOS), median progression-free survival (mPFS), median duration of response (mDOR), and treatment-related adverse events (TRAEs).
View Article and Find Full Text PDFIntra-arterial chemotherapy combined with BCG immunotherapy is more effective than intra-arterial chemotherapy plus intravesical chemotherapy or standard BCG immunotherapy in preventing the recurrence and progression of high-risk non-muscle-invasive bladder cancer.
Urol Oncol
December 2024
Department of Urology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, P.R.China. Electronic address:
Article Synopsis
- Up to 45% of high-risk non-muscle-invasive bladder cancer (NMIBC) patients may not benefit from traditional intravesical treatment, leading researchers to explore the feasibility and safety of combining it with intra-arterial chemotherapy (IAC).
- A study collected data from 143 patients diagnosed with high-risk NMIBC, dividing them into three treatment groups: one receiving only Bacillus Calmette-Guerin (BCG), another receiving BCG plus IAC, and a third receiving intravesical chemotherapy (IVC) plus IAC, with both IAC groups receiving additional courses of IAC.
- Results showed that the BCG+IAC group had significantly better recurrence and progression-free survival compared to the
Usefulness of computed tomography aortography and dye infusion in confirming the feeding arteries for effective treatment of a large squamous cell carcinoma of the lower lip with a single intra-arterial infusion chemotherapy combined with radiotherapy.
Radiol Case Rep
November 2024
Department of Radiology, Wakayama Medical University, Wakayama, Japan.
A 73-year-old male presented with a lower lip squamous cell carcinoma (SCC) (23 mm in diameter). Systemic imaging, including computed tomography (CT) and positron emission tomography, showed no evidence of distant metastasis. Due to the large size of the tumor, reconstruction after surgical tumor removal was considered to be difficult.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!